Information Provided By: 
Fly News Breaks for June 16, 2015
OMER
Jun 16, 2015 | 11:51 EDT
After Omeros announced an exclusive licensing agreement with Fagron for the commercialization of OMS103, Wedbush called the partnership deal a "clever means" to commercialize the drug instead of spending more money to seek FDA approval. The firm does not think revenues from OMS103 are likely to be material compared with OMIDRIA, but noted its model is under review and reiterated its Outperform rating and $61 price target on Omeros shares.
News For OMER From the Last 2 Days
There are no results for your query OMER
